Loading
CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. During early embryogenesis, plays essential and redundant functions with CEBPB.
CIViC holds 15 clinical evidence items and 1 assertion across 4 variants, naming Tretinoin and OICR-9429. Open Targets scores its association with cancer at 0.87 (direct and indirect evidence; datatypes genetic literature 0.80, affected pathway 0.42, literature 0.99, genetic association 0.87, somatic mutation 0.92, animal model 0.58). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia.
In plain words · CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.
CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta.
No product in this corpus aims at CEBPA yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CEBPA: RNA group enriched (adipose tissue 93 nTPM, breast 68 nTPM, liver 198 nTPM); blood lineage group enriched (dendritic cells 5 nTPM, granulocytes 16 nTPM, monocytes 16 nTPM); high antibody staining in 2 normal tissues; highest cancer staining stomach cancer (2 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute myeloid leukemia). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P49715; CIViC gene CEBPA; IntOGen CEBPA; Human Protein Atlas CEBPA tissue; Open Targets ENSG00000245848 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Antonson et al, Biochem. Biophys. Res. Commun, 1995, "Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha)". Source.
Sources: HGNC HGNC:1833 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49715 (protein name, function text, keywords and locations (REST API)); CIViC gene CEBPA (15 evidence items, 1 assertions, 4 variants; diseases: Acute Myeloid Leukaemia, Acute Myeloid Leukaemia With Mutated CEBPA (GraphQL API, CC0)); Open Targets ENSG00000245848 (association with cancer (MONDO_0004992) 0.87; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.85, myeloproliferative neoplasm 0.85, leukaemia 0.86 (GraphQL API, CC0)); IntOGen CEBPA (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung. Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage. Location: Nucleus; Nucleus, nucleolus (UniProt). Locus 19q13.11 (HGNC).
RNA: group enriched (adipose tissue 93 nTPM, breast 68 nTPM, liver 198 nTPM, skin 1 115 nTPM), detected in many normal tissues. Blood: group enriched (dendritic cells 5 nTPM, granulocytes 16 nTPM, monocytes 16 nTPM).
Medium: Caudate, Cerebral cortex, Endometrium, Kidney, Lung, Oral mucosa, Parathyroid gland, Placenta.
RNA cancer enhanced: Liver Hepatocellular Carcinoma 172 pTPM.
Medium only: colorectal cancer, ovarian cancer, prostate cancer, urothelial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CEBPA" OR ABSTRACT:"CEBPA" OR TITLE:"CCAAT enhancer binding protein alpha" OR ABSTRACT:"CCAAT enhancer binding protein alpha" OR TITLE:"CCAAT/enhancer-binding protein alpha" OR ABSTRACT:"CCAAT/enhancer-binding protein alpha" OR TITLE:"C/EBP-alpha" OR ABSTRACT:"C/EBP-alpha") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CEBPA, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, IntOGen.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, IntOGen.
Shares Acute myeloid leukaemia (KEGG map), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.